{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:59:50Z","timestamp":1780923590460,"version":"3.54.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.urolonc.2026.04.296","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:29:09Z","timestamp":1779362949000},"page":"383-390","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Salvage lymph node dissection in oligo-recurrent prostate cancer patients: Mapping patterns of recurrence and factors associated with disease progression"],"prefix":"10.1016","volume":"44","author":[{"given":"Mohamed E.","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman E.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milad","family":"Bonakdarhashemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack R.","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Reitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"Henning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyridon P.","family":"Basourakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael","family":"Zeina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carter","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene D.","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Gettman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew K.","family":"Tollefson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Jeffrey","family":"Karnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2026.04.296_bib0001","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2026.04.296_bib0002","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/CM9.0000000000000590","article-title":"Short-term therapeutic outcomes of robotic-assisted laparoscopic radical prostatectomy for oligometastatic prostate cancer: a propensity score matching study","volume":"133","author":"Chen","year":"2020","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.urolonc.2026.04.296_bib0003","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.eururo.2011.02.026","article-title":"Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence","volume":"59","author":"Boorjian","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.04.296_bib0004","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12894-023-01350-2","article-title":"Prediction of biochemical recurrence after laparoscopic radical prostatectomy","volume":"23","author":"Bejrananda","year":"2023","journal-title":"BMC Urol"},{"key":"10.1016\/j.urolonc.2026.04.296_bib0005","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/JU.0000000000003892","article-title":"Salvage therapy for prostate cancer: AUA\/ASTRO\/SUO guideline part I: introduction and treatment decision-making at the time of suspected biochemical recurrence after radical prostatectomy","volume":"211","author":"Morgan","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.04.296_bib0006","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.3390\/cancers15082316","article-title":"Review of cardiovascular risk of androgen deprivation therapy and the influence of race in men with prostate cancer","volume":"15","author":"Fradin","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.urolonc.2026.04.296_bib0007","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-24688-3","article-title":"(68)Ga-PSMA PET\/CT in early relapsed prostate cancer patients after radical therapy","volume":"12","author":"Haidar","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.urolonc.2026.04.296_bib0008","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.eururo.2015.03.036","article-title":"Natural history of clinical recurrence patterns of lymph node-positive prostate cancer after radical prostatectomy","volume":"69","author":"Moschini","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.04.296_bib0009","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12894-015-0004-y","article-title":"Targeted salvage lymphadenectomy in patients treated with radical prostatectomy with biochemical recurrence: complete biochemical response without adjuvant therapy in patients with low volume lymph node recurrence over a long-term follow-up","volume":"15","author":"Winter","year":"2015","journal-title":"BMC Urol"},{"key":"10.1016\/j.urolonc.2026.04.296_bib0010","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.euf.2016.01.008","article-title":"Mid-term outcomes following salvage lymph node dissection for prostate cancer nodal recurrence status post-radical prostatectomy","volume":"2","author":"Zattoni","year":"2016","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2026.04.296_bib0011","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.eururo.2018.10.041","article-title":"Salvage lymph node dissection for nodal recurrent prostate cancer: a systematic review","volume":"76","author":"Ploussard","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.04.296_bib0012","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S1470-2045(25)00197-4","article-title":"Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial","volume":"26","author":"Ost","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2026.04.296_bib0013","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/bju.13919","article-title":"Initial multicentre experience of (68) gallium-PSMA PET\/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited","volume":"120","author":"Siriwardana","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2026.04.296_bib0014","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s00066-014-0763-5","article-title":"Adjuvant radiotherapy after salvage lymph node dissection because of nodal relapse of prostate cancer versus salvage lymph node dissection only","volume":"191","author":"Rischke","year":"2015","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.urolonc.2026.04.296_bib0015","article-title":"Mapping of recurrence sites following adjuvant or salvage radiotherapy for prostate cancer patients","volume":"11","author":"Gonzalez-Moya","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2026.04.296_bib0016","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/pcan.2016.54","article-title":"The role of salvage extended lymph node dissection in patients with rising PSA and PET\/CT scan detected nodal recurrence of prostate cancer","volume":"20","author":"Porres","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urolonc.2026.04.296_bib0017","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.eururo.2011.07.060","article-title":"Pelvic\/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography\/computed tomography","volume":"60","author":"Rigatti","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.04.296_bib0018","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.eururo.2014.02.011","article-title":"Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years","volume":"67","author":"Suardi","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.04.296_bib0019","first-page":"e1021","article-title":"11C-Choline versus 68ga-Psma pet\/Ct scan for the detection of nodal recurrence from prostate cancer: results from a large, multi-institutional salvage lymph node dissection series: mp77-01","volume":"197","author":"Fossati","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.04.296_bib0020","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.3390\/cancers12113395","article-title":"Outcome after 68Ga-PSMA-11 versus choline PET-based salvage radiotherapy in patients with biochemical recurrence of prostate cancer: a matched-pair analysis","volume":"12","author":"Schmidt Hegemann","year":"2020","journal-title":"Cancers"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:04:31Z","timestamp":1780920271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926005053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1078143926005053"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.04.296","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Salvage lymph node dissection in oligo-recurrent prostate cancer patients: Mapping patterns of recurrence and factors associated with disease progression","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.04.296","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}